The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.
Open accessAbstract
Enzymes within the P450IIIA (CYP3A) subfamily appear to account for significant "first pass" metabolism of some drugs in the intestine. To identify which of the known P450IIIA genes are expressed in intestine, enterocyte RNA was hybridized on Northern blots with synthetic oligonucleotides complementary to hypervariable regions of hepatic P450IIIA4, P450IIIA5, and P450IIIA7 cDNAs. Hybridization was detected only with the P450IIIA4-specific oligonucleotide. The identity of the hybridizing mRNA was confirmed to be P450IIIA4 by direct sequencing of a DNA fragment amplified from enterocyte cDNA by the polymerase chain reaction. To determine if enterocyte P450IIIA4 is inducible, biopsies of small bowel mucosa were obtained from five volunteers before and after they received 7d of treatment with rifampin, a known inducer of P450IIIA4 in liver. Rifampin treatment resulted in a five- or eightfold mean increase (P < 0.05) in the biopsy concentration of P450IIIA4 mRNA when normalized for content of sucrase isomaltase or intestinal fatty acid binding protein mRNAs, respectively. Rifampin also induced P450IIIA immunoreactive protein in enterocytes in each of the subjects, as judged by immunohistochemistry, and resulted in a 10-fold increase in P450IIIA4-specific catalytic activity (erythromycin N-demethylation) in the one patient studied. Our identification of inducible P450IIIA4 in enterocytes may in part account for drug interactions characteristic of P450IIIA4 substrates and suggests a strategy for controlling entry into the body of a major class of xenobiotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
The colorimetric estimation of formaldehyde by means of the Hantzsch reaction
Nash, T. (1953) · Biochemical Journal · doi:10.1042/bj0550416 · Cited by 4,371
The P450 Superfamily: Update on New Sequences, Gene Mapping, and Recommended Nomenclature
NEBERT, D. W., NELSON, D. R., COON, M. J., ESTABROOK, R. W., FEYEREISEN, R., FUJII-KURIYAMA, Y., GONZALEZ, F. J., GUENGERICH, F. P., GUNSALUS, I. C., JOHNSON, E. F., et al. (1991) · DNA and Cell Biology · doi:10.1089/dna.1991.10.1 · Cited by 1,094
Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T., & Waxman, D. J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)89213-x · Cited by 724
Kronbach, T., Fischer, V., & Meyer, U. A. (1988) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1988.87 · Cited by 533
Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.
Kronbach, T., Mathys, D., Umeno, M., Gonzalez, F. J., & Meyer, U. A. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09118-7 · Cited by 532
Clinical Pharmacokinetics of Cyclosporin
Ptachcinski, R. J., Venkataramanan, R., & Burckart, G. J. (1986) · Clinical Pharmacokinetics · doi:10.2165/00003088-198611020-00002 · Cited by 493
Aoyama, T., Yamano, S., Waxman, D. J., Lapenson, D. P., Meyer, U. A., Fischer, V, Tyndale, R., Inaba, T., Kalow, W., Gelboin, H. V., et al. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)81632-5 · Cited by 482
Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T., & Guzelian, P. S. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113156 · Cited by 480
Self-citation
Cited by
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M., & Wilkinson, G. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1269 · Cited by 1,054
SXR, a novel steroid and xenobioticsensing nuclear receptor
Blumberg, B., Sabbagh, W., Juguilon, H., Bolado, J., van Meter, C. M., Ong, E. S., & Evans, R. M. (1998) · Genes & Development · doi:10.1101/gad.12.20.3195 · Cited by 919
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date review
Tostmann, A., Boeree, M. J., Aarnoutse, R. E., De Lange, W. C. M., Van Der Ven, A. J. A. M., & Dekhuijzen, R. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05207.x · Cited by 781
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Grapefruit juice–drug interactions
Bailey, D. G., Malcolm, J., Arnold, O., & David Spence, J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00764.x · Cited by 740
Guengerich, F. P. (1995) · Cytochrome P450 · doi:10.1007/978-1-4757-2391-5_14 · Cited by 728
Lown, K. S., Mayo, R. R., Leichtman, A. B., Hsiao, H.-L., Turgeon, D. K., Schmiedlin-Ren, P., Brown, M. B., Guo, W., Rossi, S. J., Benet, L. Z., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90027-8 · Cited by 680
Self-citationHumanized xenobiotic response in mice expressing nuclear receptor SXR
Xie, W., Barwick, J. L., Downes, M., Blumberg, B., Simon, C. M., Nelson, M. C., Neuschwander-Tetri, B. A., Brunt, E. M., Guzelian, P. S., & Evans, R. M. (2000) · Nature · doi:10.1038/35019116 · Cited by 660
Lown, K. S., Bailey, D. G., Fontana, R. J., Janardan, S. K., Adair, C. H., Fortlage, L. A., Brown, M. B., Guo, W., & Watkins, P. B. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119439 · Cited by 624
Self-citationThummel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., & Wilkinson, G. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90177-0 · Cited by 617
The Gut as a Barrier to Drug Absorption: Combined Role of Cytochrome P450 3A and P-Glycoprotein
Zhang, Y., & Benet, L. Z. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140030-00002 · Cited by 518
Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., & Sugiyama, Y. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01372-3 · Cited by 512
Population-Based Mechanistic Prediction of Oral Drug Absorption
Jamei, M., Turner, D., Yang, J., Neuhoff, S., Polak, S., Rostami-Hodjegan, A., & Tucker, G. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9099-y · Cited by 452
The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338
King, A. J., Sun, H., Diaz, B., Barnard, D., Miao, W., Bagrodia, S., & Marshall, M. S. (1998) · Nature · doi:10.1038/24184 · Cited by 443
Abernethy, D. R., & Schwartz, J. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911043411907 · Cited by 443
Extrahepatic Metabolism of Drugs in Humans
Krishna, D. R., & Klotz, U. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199426020-00007 · Cited by 437
Increased drug delivery to the brain by P-glycoprotein inhibition
Sadeque, A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109156 · Cited by 426
Wacher, V. J., Silverman, J. A., Zhang, Y., & Benet, L. Z. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980082d · Cited by 423
Inhibition and induction of CYP enzymes in humans: an update
Hakkola, J., Hukkanen, J., Turpeinen, M., & Pelkonen, O. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02936-7 · Cited by 418
Gorski, J. C., Jones, D. R., Haehner-Daniels, B. D., Hamman, M. A., O'Mara, E. M., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90146-1 · Cited by 411
Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans
Glaeser, H., Bailey, D. G., Dresser, G. K., Gregor, J. C., Schwarz, U. I., McGrath, J. S., Jolicoeur, E., Lee, W., Leake, B. F., Tirona, R. G., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100056 · Cited by 407
Khoo, S.-M., Humberstone, A. J., Porter, C. J. H., Edwards, G. A., & Charman, W. N. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00054-4 · Cited by 396
The barrier function of CYP3A4 and P-glycoprotein in the small bowel
Watkins, P. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00041-0 · Cited by 391
Self-citationCao, X., Gibbs, S. T., Fang, L., Miller, H. A., Landowski, C. P., Shin, H.-C., Lennernas, H., Zhong, Y., Amidon, G. L., Yu, L. X., et al. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9041-2 · Cited by 388
Jamei, M., Dickinson, G. L., & Rostami-Hodjegan, A. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.53 · Cited by 368
Inhibition and induction of human cytochrome P450 (CYP) enzymes
PELKONEN, O., MÄEENPÄEÄ, J., TAAVITSAINEN, P., RAUTIO, A., & RAUNIO, H. (1998) · Xenobiotica · doi:10.1080/004982598238886 · Cited by 358
Dai, D., Tang, J., Rose, R., Hodgson, E., Bienstock, R. J., Mohrenweiser, H. W., & Goldstein, J. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29199-0 · Cited by 357
Is the Role of the Small Intestine in First-Pass Metabolism Overemphasized?
Lin, J. H., Chiba, M., & Baillie, T. A. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01402-9 · Cited by 352
Drug Interactions with Grapefruit Juice
Ameer, B., & Weintraub, R. A. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733020-00003 · Cited by 348
Disposition of intravenous and oral cyclosporine after administration with grapefruit juice*
Ducharme, M. P., Warbasse, L. H., & Edwards, D. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90032-2 · Cited by 347
Characterization of Human Small Intestinal Cytochromes P-450
Zhang, Q.-Y., Dunbar, D., Ostrowska, A., Zeisloft, S., Yang, J., & Kaminsky, L. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15229-4 · Cited by 343
Cytochrome P450-mediated metabolism in the human gut wall
Thelen, K., & Dressman, J. B. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.05.0002 · Cited by 338
Andersson, T. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631010-00002 · Cited by 326
Schmiedlin-Ren, P., Thummel, K. E., Fisher, J. M., Paine, M. F., Lown, K. S., & Watkins, P. B. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.5.741 · Cited by 325
Self-citationEnzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
Thummel, K. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00039-2 · Cited by 318
Possible involvement of pregnane X receptor–enhanced CYP24 expression in drug-induced osteomalacia
Pascussi, J., Robert, A., Nguyen, T. M., Walrant-Debray, O., Garabédian, M., Martin, P. G. P., Pineau, T., Saric, J., Navarro, F., Maurel, P., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200521867 · Cited by 317
Clinical Pharmacokinetics and Pharmacodynamics of Buspirone, an Anxiolytic Drug
Mahmood, I., & Sahajwalla, C. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936040-00003 · Cited by 309
Active secretion and enterocytic drug metabolism barriers to drug absorption
Wacher, V. J., Salphati, L., & Benet, L. Z. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00127-s · Cited by 308
Genetic Variability in CYP3A5 and its Possible Consequences
Xie, H.-G., Wood, A. J., Kim, R. B., Stein, C. M., & Wilkinson, G. R. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.3.243.29833 · Cited by 302
First-pass metabolism of midazolam by the human intestine*
Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., Marsh, C. L., McVicar, J. P., Barr, D. M., Gillies, B. S., & Thummel, K. E. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90162-9 · Cited by 302
Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by Human CYP3A4
Thummel, K. E., Lee, C. A., Kunze, K. L., Nelson, S. D., & Slattery, J. T. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90295-8 · Cited by 296
Chen, J., & Raymond, K. (2006) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-5-3 · Cited by 296
Zhang, J., Kuehl, P., Green, E. D., Touchman, J. W., Watkins, P. B., Daly, A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00003 · Cited by 292
Self-citationUnmasking the Dynamic Interplay between Intestinal P-Glycoprotein and CYP3A4
Cummins, C. L., Jacobsen, W., & Benet, L. Z. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1036 · Cited by 289
Clinical Pharmacokinetics and Metabolism of Chloroquine: Focus on Recent Advancements
Ducharme, J., & Farinotti, R. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631040-00003 · Cited by 289
Hebert, M. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00043-4 · Cited by 288
Interindividual Variability in Inhibition and Induction of Cytochrome P450 Enzymes
Lin, J. H., & Lu, A. Y. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.535 · Cited by 285
Westphal, K. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109797 · Cited by 285
Differential Induction of Prehepatic and Hepatic Metabolism of Verapamil by Rifampin
Fromm, M. F., Busse, D., Kroemer, H. K., & Eichelbaum, M. (1996) · Hepatology · doi:10.1002/hep.510240407 · Cited by 283
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*
Gomez, D. Y., Wacher, V. J., Tomlanovich, S. J., Hebert, M. F., & Benet, L. Z. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90067-5 · Cited by 282
Ito, K., Iwatsubo, T., Kanamitsu, S., Nakajima, Y., & Sugiyama, Y. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.461 · Cited by 282
Systemic Antifungal Agents: Drug Interactions of Clinical Significance
Albengres Herv??, E., Lou??, L., & Tillement, J.-P. (1998) · Drug Safety · doi:10.2165/00002018-199818020-00001 · Cited by 280
The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters
Fromm, M. F., Kauffmann, H.-M., Fritz, P., Burk, O., Kroemer, H. K., Warzok, R. W., Eichelbaum, M., Siegmund, W., & Schrenk, D. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64794-3 · Cited by 277
P-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine
Mouly, S., & Paine, M. F. (2003) · Pharmaceutical Research · doi:10.1023/a:1026183200740 · Cited by 276
Hasler, J. A., Estabrook, R., Murray, M., Pikuleva, I., Waterman, M., Capdevila, J., Holla, V., Helvig, C., Falck, J. R., Farrell, G., et al. (1999) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(99)00005-9 · Cited by 267
Backman, J. T., Kivistö, K. T., Olkkola, K. T., & Neuvonen, P. J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050420 · Cited by 266
Schuetz, E. G., Schinkel, A. H., Relling, M. V., & Schuetz, J. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4001 · Cited by 266
Self-citationPharmacokinetics in the newborn
Alcorn, J., & McNamara, P. J. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00030-9 · Cited by 266
CYP induction-mediated drug interactions: in vitro assessment and clinical implications
Lin, J. H. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0277-7 · Cited by 264
Pharmacokinetic variability of anticancer agents
Undevia, S. D., Gomez-Abuin, G., & Ratain, M. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1629 · Cited by 258
von Richter, O., Burk, O., Fromm, M. F., Thon, K. P., Eichelbaum, M., & Kivistö, K. T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.008 · Cited by 255
MDR- and CYP3A4-mediated drug–herbal interactions
Pal, D., & Mitra, A. K. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.010 · Cited by 254
TANNERGREN, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.012 · Cited by 138
Symposium Article: Molecular and Physical Mechanisms of First-Pass Extraction
Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Benet, L. Z., Paine, M. F., Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15271-3 · Cited by 109
Self-citationVitamin D and drug-metabolising enzymes
Lindh, J. D., Björkhem-Bergman, L., & Eliasson, E. (2012) · Photochemical & Photobiological Sciences · doi:10.1039/c2pp25194a · Cited by 22
Metadata
- Authors
- Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C., & Watkins, P. B.
- Venue
- Journal of Clinical Investigation
- Published
- 1992-11-01
- Volume
- 90
- Issue
- 5
- Pages
- 1871-1878
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2024587809
- Cited by
- 528
- References
- 38
- FWCI
- 14.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.